Immunome Inc. — Director's Dealing 2022

Jun 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2022-06-16

Reporting Person: Roche Corleen M. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-16	Stock Option (Right to Buy)	$3.42	A	70000	Acquired	2032-06-16	Common Stock (70000)	Direct

Footnotes

F1: With respect to the options to purchase 40,000 shares, 25% of the shares subject to such options vest on June 16, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to such options shall vest every month thereafter. With respect to the remaining options to purchase 30,000 shares, 50% of the shares subject to such options vest on June 16, 2023, and the remaining 50% of the shares subject to such options vest on June 16, 2024.